Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Custom Solutions
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
BioVex
December 13, 2016
Setbacks fail to stifle oncolytic virus business development
April 30, 2015
Adcom puts T-Vec on track to underwhelm
April 07, 2014
Near miss for T-Vec limits future as solo artist
June 03, 2013
Asco – Despite promise, future of oncolytic viruses remains clouded
March 20, 2013
Will Amgen's success be infectious for oncolytic viruses?
February 07, 2013
M&A activity cools in 2012 as break-ups loom
November 24, 2011
History not on Gilead's side in high stakes gamble on Pharmasset
August 25, 2011
Most valuable unpartnered pipeline assets – what's hot and what's not
August 23, 2011
Encouraging 2011 M&A trends seen but big pharma inactivity concerning
May 23, 2011
BioEquity - Big pharma slowing the pace of deals
May 12, 2011
EP Vantage Interview - PsiOxus seeking to ride oncolytic virus wave
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 03, 2021
Biopharma and Medtech Half-Year Review 2021
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
Editor's Picks
September 13, 2021
Esmo 2021 – Mirati bids to be belle of the ball
September 03, 2021
World Lung 2021 preview – China challenges and tremelimumab rises
September 07, 2021
Roche U-turns and Adaptimmune wins
September 02, 2021
Tecentriq pullout dominates the latest PD-(L)1 moves
September 06, 2021
Another gene therapy safety scare hits
